<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710420</url>
  </required_header>
  <id_info>
    <org_study_id>PRIME-WIFI</org_study_id>
    <nct_id>NCT04710420</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Registry on the Endovascular Treatment in Critical Limb Threatening Ischemia With Below the Knee Lesions With Wound, Ischemia, and Foot Infection (WIFI) Assessment</brief_title>
  <official_title>Prospective Multicenter Registry on the Endovascular Treatment in Critical Limb Threatening Ischemia With Below the Knee Lesions With WIFI Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao haici hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter clinical study that used WIFI grading scores at different&#xD;
      periods to evaluate the therapeutic value of endovascular therapy and this grading system for&#xD;
      Chronic limb-threatening ischemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The composite end point</measure>
    <time_frame>12 months</time_frame>
    <description>Death from CLTI, major amputation rates and clinical driven target lesion revascularization (CDTLR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WIfI stages</measure>
    <time_frame>12 months</time_frame>
    <description>Before follow-up and during each follow-up, the Society for Vascular Surgery wound, ischemia, and foot Infection (WIfI) were evaluated classification system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event rates</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse event rates includes surgically related arterial dissection, perforation, rupture, embolism, acute thrombosis, pseudoaneurysm and hematoma formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford categories</measure>
    <time_frame>12 months</time_frame>
    <description>Rutherford categories were evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABI</measure>
    <time_frame>12 months</time_frame>
    <description>Ankle brachial index was evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TcPO2</measure>
    <time_frame>12 months</time_frame>
    <description>Transcutaneous pressure of oxygen was evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wagner's grades</measure>
    <time_frame>12 months</time_frame>
    <description>For Rutherford categories from 5 to 6, the Wagner's grades ranges from 0 to 5, grade 5 means the worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization time</measure>
    <time_frame>12 months</time_frame>
    <description>The length of hospital stay was evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization expenses</measure>
    <time_frame>12 months</time_frame>
    <description>Hospitalization costs for patients were evaluated</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Chronic Limb-threatening Ischemia</condition>
  <condition>Endovascular Therapy</condition>
  <arm_group>
    <arm_group_label>WIfI composite 1-4</arm_group_label>
    <description>Summing the three individual WIfI components together, the WIfI composite score 1-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WIfI composite 5-9</arm_group_label>
    <description>Summing the three individual WIfI components together, the WIfI composite score 5-9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular therapy</intervention_name>
    <description>Endovascular treatment for critical limb threatening Ischemia</description>
    <arm_group_label>WIfI composite 1-4</arm_group_label>
    <arm_group_label>WIfI composite 5-9</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Chronic limb-threatening ischemia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients with Chronic limb-threatening ischemia (CLTI);&#xD;
&#xD;
          2. patients voluntary and capable of follow-up;&#xD;
&#xD;
          3. patients &gt; 18 years of age;&#xD;
&#xD;
          4. informed consent.&#xD;
&#xD;
        Definition of CLTI:&#xD;
&#xD;
          1. the presence &gt; 2weeks duration;&#xD;
&#xD;
          2. arteriosclerosis is related;&#xD;
&#xD;
          3. ankle-brachial index (ABI) &lt; 0.4, absolute highest ankle arterial pressure &lt;50 mmHg,&#xD;
             absolute toe arterial pressure &lt;30 mmHg, transcutaneous partial pressure of oxygen&#xD;
             (TcPO2) &lt; 30 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication for antiplatelet , anticoagulant or thrombolytic agent;&#xD;
&#xD;
          2. Contrast agent allergy;&#xD;
&#xD;
          3. Dysfunctional protein C, protein S, antithrombin Ⅲ(AT Ⅲ) or refusal of blood&#xD;
             transfusion;&#xD;
&#xD;
          4. Life expectancy &lt; 12 months;&#xD;
&#xD;
          5. Interventional treatment was adopted to the target artery within 1 year;&#xD;
&#xD;
          6. Elective operation is to be performed within 30 days except surgical intervention in&#xD;
             this clinical study;&#xD;
&#xD;
          7. Participation in other clinical study;&#xD;
&#xD;
          8. Complications affecting surgical safety;&#xD;
&#xD;
          9. Chronic Kidney Disease(CKD);&#xD;
&#xD;
         10. Major amputation was adopted to the target extremity;&#xD;
&#xD;
         11. The existence of aneurysm in the target vessels;&#xD;
&#xD;
         12. The existence of perforation, dissection or any other injury requiring intervention in&#xD;
             the target vessels.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianming Guo, M.D.</last_name>
    <phone>13146369562</phone>
    <email>guojianming1020@icloud.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lianrui Guo, M.D.</last_name>
    <phone>13671009746</phone>
    <email>lianruiguo@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianming Guo, M.D.</last_name>
      <phone>13146369562</phone>
      <email>guojianming@icloud.com</email>
    </contact>
    <contact_backup>
      <last_name>Lianrui Guo, M.D.</last_name>
      <phone>13671009746</phone>
      <email>lianruiguo@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Lian-Rui Guo</investigator_full_name>
    <investigator_title>Director, vascular suregry department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

